-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A vaccine based on the SARS-CoV-2 spike protein is currently being launched globally to control transmission and limit the morbidity and mortality caused by the new coronavirus pneumonia
.
Current evidence indicates, BNT162b2 (Pfizer - Biotechnology company) and ChAdOx1ncov-19 (Oxford - AstraZeneca) of immune immunogenicity and short-term effects are strong
After immunization for 3-4 weeks, it is expected to maximize the first dose coverage and immunogenicity
In order to determine the early signs of the decline in the spike protein (S antibody) antibody level after the completion of two doses of vaccination, MadhumitaShrotri et al
They submitted a capillary vascular blood samples for virus observed
.
Serum detection uses electronic anti-SARS-CoV-2 S and N electrochemiluminescence immunoassay (Roche Diagnostics , Basel, Switzerland); S detection of total antibodies against the spike protein s1 subunit (0.
Vascular diagnosis
605 adults will submit valid samples from June 14 to 15, 2021
.
Of the 605 participants, 321 (53%) were women, with an average age of 63 years (IQR58-67)
Anti-SARS-CoV-2 spike protein (S antibody) antibody levels in individuals who have not been infected with SARS-CoV-2 at a specific time point after the second vaccination (extended dose interval)
Anti-SARS-CoV-2 spike protein (S antibody) antibody levels in individuals who have not been infected with SARS-CoV-2 at a specific time point after the second vaccination (extended dose interval)In the two types of vaccines, women have higher initial S antibody levels 21-42 days after full vaccination than men; they also end up at higher levels within 70 days or longer
.
Similarly, compared with elderly people aged 65 and above, elderly people aged 18-64 have a higher level at 21-42 days, and the level at 70 days and above is correspondingly higher
There is substantial potential heterogeneity in the clinically vulnerable population, and it is also restricted by a few people in the clinically vulnerable population.
Preliminary data indicate that xenogeneic vaccination will trigger stronger antibody and T cell responses, may provide longer-lasting immunity, and provide greater protection against emerging mutations.
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
https://doi.
org/10.
1016/S0140-6736(21)01642-1 Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
https://doi.
org /10.
1016/S0140-6736(21)01642-1 https://doi.
org/10.
1016/S0140-6736(21)01642-1 Leave a message here
